View the complete Missouri Regional Life Sciences Summit supplement from the Kansas City and St. Louis Business Journals. Click here to view.
Click a name to learn more about each speaker.
William H. Danforth is currently chancellor emeritus of Washington University.
He chairs the Coalition of Plant and Life Sciences and is chairman of the board of directors of the Donald Danforth Plant Science Center.
Born in St. Louis on April 10, 1926, he received his bachelor's degree from Princeton University and his medical degree from Harvard Medical School in 1951. After completing his internship in medicine at Barnes Hospital, St. Louis, he served in the United States Navy from 1952-54. He returned to St. Louis to continue his medical training at Barnes Hospital and at St. Louis Children's Hospital.
Danforth joined the Washington University Medical School faculty in 1957. In 1967, he was appointed professor of internal medicine, which is his present faculty rank at the university. From 1965-71, Danforth served as vice chancellor for medical affairs and as president of the Washington University Medical Center. Danforth became Washington University's 13th chancellor July 1, 1971 and served until his retirement June 30, 1995. During this time the university recruited many eminent plant scientists. He also served as chairman of the board of trustees of Washington University from July 1, 1995 to June 30, 1999. Danforth is a member of the Institute of Medicine and served on the council 1977-79.
Danforth was appointed to chair the Research, Education and Economics Task Force for the USDA by Agriculture Secretary Ann M. Veneman in 2003. The task force reported in 2004. That report led to legislation by Congress that established the National Institute for Food and Agriculture, which began with great hopes for support for high quality agricultural research.
He is a director on the board of trustees of the Danforth Foundation and is a trustee of the American Youth Foundation. He co-chaired of the board of directors of Barnes-Jewish Hospital and served on the boards of directors of Ralston Purina Co., McDonnell-Douglas Corp., BJC Health System and Energizer Holdings Inc. (return to contents)
Scott Peterson received his undergraduate education at Rutgers University from 1982-1986. Peterson then pursued a doctorate in the laboratory of Clyde Hutchison at the University of North Carolina at Chapel Hill, where he initiated a characterization of the minimal genome of mycoplasma genitalium. Peterson did post-doctoral studies at Glaxo-Wellcome Inc. from 1992-1996. Peterson joined the faculty in 1996 where he has pursued a wide variety of functional and comparative genomics studies.
Peterson was the co-first author on the global transposon mutagenesis of the M. genitalium genome to define the minimal genetic requirements for life. Peterson has been using DNA microarrays to conduct gene expression and comparative genomic hybridization studies on a number of bacterial species. More recently, Peterson has developed novel applications using DNA microarrays to enhance the efficiency of performing functional characterization of microbial genomes. Since 2001, Peterson has been the Scientific Director of the NIAID's Pathogen Functional Genomics Resource Center. As the scientific leader of the PFGRC, Peterson has developed additional areas of expertise in functional genomics, particularly focused on high throughput gene cloning and protein expression and proteomics.
Peterson is interested in the evolution of pathogenic genomes. More recently, Peterson has developed a number of methods and strategies to enable deeper characterization of metagenomes and has interest in both human and environmental metagenomics. In 2008, Peterson was promoted to the position of director of functional genomics research and development. (return to contents)
Jerry holds the Wurdack Chair in Animal Genomics at the University of Missouri-Columbia. He is an elected AAAS Fellow and is the 2008 Celebration of Excellence Distinguished Researcher in the College of Agriculture, Food and Natural Resources. He is an honorary scientist and scientific adviser on agricultural green tTechnology to the Rural Development Administration of the Republic of Korea. He is a member of the iBMAC Consortium which won the 2008 USDA Technology Transfer Award and the 2009 FLC Award for Excellence in Technology Transfer. He has received $20 million in competitive research funding and has authored 149 peer reviewed research articles. He has served on the Scientific Advisory Board for Sigma-Aldrich Biotechnology, was director of genomics at RTI International and was cofounder, board member and a senior executive of GenomicFX an agricultural biotechnology company. Jerry received a doctorate in quantitative genetics from the University of New England in Australia. (return to contents)
Samuel A. Wickline is professor of medicine, physics, biomedical engineering, and cell biology and physiology at Washington University. He received the bachelor's degree from Pomona College, Claremont, Calif., in 1974 and his medical degree from the University of Hawaii School of Medicine, Honolulu, in 1980. He completed post-doctoral training in internal medicine and cardiology at Barnes Hospital, St. Louis, in 1987 and joined the faculty of the School of Medicine in the Cardiovascular Division before becoming director of the cardiovascular division at Jewish Hospital and subsequently co-director of the cardiovascular division at Barnes-Jewish Hospital. He is co-director of the cardiovascular bioengineering graduate Program at Washington University and a member of the executive faculty of the Institute for Biological and Medical Engineering. He established the Washington University Consortium for Translational Research in Advanced Imaging and Nanomedicine (C-TRAIN) at the St Louis CORTEX Center devoted to diagnostic and therapeutic development of nanotechnology in concert with corporate and academic partners for broadbased clinical applications. He also directs the Siteman Center For Cancer Nanotechnology Excellence at Washington University. Wickline is a founder of two local biotech startup companies in St Louis: Kereos Inc., a nanotechnology startup company devoted to molecular imaging and targeted therapeutics; and PixelEXX Systems Inc., a company that makes semiconductor nanoarrays for molecular diagnostics and microscopy. He also directs the new St. Louis Institute of Nanomedicine, a consortium of academic and commercial partners devoted to enhancing regional infrastructure for the translational advancement of nanotechnology in medicine. He is the author of over 200 research papers, and holds more than 50 issued or filed U.S. patent applications. (return to contents)
Peter Koulen, UMKC professor and Felix and Carmen Sabates Missouri Endowed Chair in Vision Research, concentrates his research on the action and development of pharmacological and molecular biological treatments of disorders of the eye and brain. Koulen studies diseases resulting in visual decline during the aging process and in diabetes patients as well as the loss of function and quality of life associated with Alzheimer's disease and stroke.
Koulen co-directs the Vision Research Center, a facility bringing recognition to Kansas City as a source of new research into the causes and prevention of blindness, the development of new therapies and diagnostics technology through translational medicine, technology transfer and state-of-the-art clinical research and care.
Koulen received his doctorate from Johannes Gutenberg University in Mainz, Germany and was trained at the Max-Planck Institute for Brain Research in Frankfurt, Germany, the Marine Biological Laboratory in Woods Hole, Mass., and Yale University School of Medicine. (return to contents)
Marco Brotto is an associate professor of nursing, medicine and biological sciences and director of the UMKC Muscle Biology Research Group. He is an editorial board member for the Journal of Pharmacology and Experimental Therapeutics and Co-Director of the American Physiological Society Muscle Biology Group.
Brotto's research focuses on understanding the cellular and molecular make-up and function of skeletal and cardiac muscles. He is particularly interested in understanding the process of muscle fatigue and muscle aging. Brotto utilizes a multidisciplinary approach in his research efforts. His research is currently funded by the American Heart Association, Missouri Life Sciences Research Board and National Institutes of Health.
Since childhood, Brotto has been interested in how muscles function. That interest has become a desire to find ways to improve the overall health of the human body. (return to contents)
Nelson Sabates is professor and chairman, department of ophthalmology at UMKC School of Medicine and president of the Vision Research Foundation. He is a 1986 graduate of the UMKC School of Medicine, where he was a member of the Alpha Omega Alpha medical honor society.
As co-director of UMKC's Vision Research Center, Dr. Sabates' research interests include treatment of age related macular degeneration and diabetic retinopathy. He also is president/CEO of the Sabates Eye Centers in Kansas City, a multiple-location practice devoted to the diagnosis and treatment of a wide range of vision problems. (return to contents)
Wynn A. Volkert's research program has been focused primarily on development and applications of novel radiolabeled agents that are used for the diagnosis and treatment of human cancers and other disease processes.
He has over 30 years of experience in this area and was the principal investigator of a NCI/NIH funded In Vivo Cellular and Molecular Imaging Center at MU. Results from research performed by him, students and colleagues include the design and development of two radiopharmaceuticals that are approved for routine use in humans by the U.S. Food and Drug Administration. One is a diagnostic imaging agent (Ceretec) that is used for imaging a variety of neurological and infectious disorders and the second is a radiotherapeutic agent (Quadramet) that is used to treat painful bone cancer lesions that are associated with skeletal metastases.
Volkert's experience and background in radiation biology enabled him to play a leadership role in developing and conducting radiotoxicology studies in animals that were required for the design of the clinical trial protocols to assess the safety and efficacy of Quadramet in humans. He has been worked closely with the UM in filing patents and licensing of technologies that evolved from basic and applied research programs in radiopharmaceutical sciences and nuclear medicine. (return to contents)
David W. Kemper is chairman, president and CEO of Commerce Bancshares Inc., a $17.9 billion regional bank holding company based in Missouri.
Kemper's first career assignment came in 1975, with a two-year post with New York-based Morgan Guaranty Trust Co. He started with Commerce in 1978.
Kemper graduated cum laude from Harvard University in 1972. He received a master's degree in English literature from Oxford University in 1974 and an MBA from Stanford Graduate School of Business (1976).
Kemper is a director of Tower Properties Company and Ralcorp Holdings Inc., and serves as an advisory director for Enterprise Rent-A-Car and Bunge North America. He serves as a board member of Washington University, the Missouri Botanical Garden and the Donald Danforth Plant Science Center. He is the past president of the Federal Advisory Council of the Federal Reserve and a director of the Financial Services Roundtable. He is also a member of Civic Progress in St. Louis. (return to contents)
Lynda F. Bonewald received her doctorate in 1984 from the Medical University of South Carolina in immunology and microbiology, performed her postdoctoral fellowship with Makio Ogawa in the area of hemopoeitic stem cell growth factors, before joining Gregory Mundy's group at the University of Texas Health Science Center in San Antonio in 1986 as an assistant professor.
Upon moving to UMKC in 2001, she was a full professor bringing one program project and two R01s. Her research focuses on osteocyte biology and she is director of an NIH program project entitled "Osteocyte Function and Effects of Mechanical Strain." She is an associate editor for Journal for Bone and Mineral Research and serves on the editorial boards for the Journal for Biomolecular Techniques, Bone and Experimental Biology and Medicine. She is the recipient of the Distinguished Scientist Award in the area of mineralized tissue from AADR/IADR and the Remodeling in Bone Award from the Sun Valley Workshop. She now serves as secretary/treasurer for the American Society for Bone and Mineral Research. (return to contents)
As senior vice president and director of technical operations for Midwest Research Institute, Sack is responsible for the institute's research operations, which generate about $100 million annually in revenue. He directs more than 580 staff members working on projects in the fields of national security/defense, life sciences, energy and the environment, and food/agriculture. The research facilities in Kansas City, Rockville, Md. and Palm Bay, Fla., that Sack oversees include more than 355,000-square foot of state-of-the-art laboratories and administrative offices; two rural field stations; and a mobile laboratory production facility. Sack received a bachelor's in chemistry from Rockhurst College and a doctorate in analytical chemistry from the University of Nebraska-Lincoln. He has coauthored more than 50 publications and technical papers. In addition, Sack is a member of several professional organizations and serves on several civic and technical boards and committees. (return to contents)
Russell Swerdlow is the director of the neurodegenerative disorders program and a professor in the departments of neurology and molecular and integrative physiology at the University of Kansas School of Medicine. He received his undergraduate and doctor of medicine degrees from New York University and trained as a neurologist and cognitive disorders subspecialist at the University of Virginia. In addition to his clinical side, Swerdlow is a laboratory-based neuroscientist who is internationally known for his work on mitochondrial dysfunction in neurodegenerative diseases. Swerdlow's laboratory studies the interaction between genes and cell energy metabolism, the molecular consequences of altered cell energy metabolism and strategies for repairing defective energy metabolism. The goals of this work are to better understand the molecular mechanisms that underlie brain aging and neurodegeneration, and to develop treatments for neurodegenerative diseases that have impaired energy metabolism including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. (return to contents)
As director of technology and economic development at Missouri University of Science and Technology, Keith Strassner is focused on expanding the economic footprint of the university through commercialization of the university's technology. He represents the university as a board member of the Rolla Regional Economic Commission and on the board of Missouri Enterprise. Previously he served as assistant director for Alliances at Brewer Science Inc., responsible for the identification and development of strategic alliances and partnerships leading to the creation new business opportunities, including a key role in the formation of the Jordan Valley Innovation Center at Missouri State University (Springfield, Mo.). Before joining Brewer Science, he spent 16 years with Petrolite Corporation, a specialty chemical company based in St. Louis and Tulsa, Okla., holding a variety of technical, business development and marketing positions including manager of new business development and research and development manager. (return to contents)
Since 1982 Randall Prather's research has focused on the early mammalian embryo. He earned his bachelor's degree and master's degreefrom Kansas State University and a doctorate from the University of Wisconsin-Madison, where he also did post doctoral work. While at Wisconsin he cloned some of the first cattle by nuclear transfer and the first pigs. His group at the University of Missouri has created miniature pigs that have the alpha 1,3 galactosyltransferase gene knocked out, thus paving the way for xenotransplantation; and have developed pigs that have cystic fibrosis, thus providing the first whole animal model that can be used to study the disease. In addition to his transgenic pig research, he and his collaborators have identified newly described genes in the reproductive tissues of pigs and cattle that will help develop an understanding of the pattern of gene expression to reduce the 30 percent loss of pregnancies that occurs in mammals. (return to contents)
Dennis O'Brien is the chancellor's chair of excellence in comparative neurology in the Department of Veterinary Medicine and Surgery at the University of Missouri-Columbia College of Veterinary Medicine. He received his doctor of veterinary medicine degree from the University of Illinois in 1975. After three years in general practice, he returned to the University of Illinois to complete a residency in neurology in 1981 and a doctorate in neuroscience in 1987. He is board certified in neurology by the American College of Veterinary Internal Medicine and has served as president of the ACVIM Specialty of Neurology. He is staff neurologist at the MU Veterinary Medical Teaching Hospital. He also directs the Comparative Neurology Program at the University of Missouri-Columbia which explores the role of genetics in developmental and degenerative diseases of the nervous system and then translates that knowledge into improved diagnostic and therapeutic modalities to benefit both animals and humans. (return to contents)
K. Krishnamurthy received his bachelor's degree in mechanical engineering from Bangalore University, India, and his master's and doctorate degrees from Washington State University, Pullman, Wash. He is the vice provost for research and a professor of mechanical engineering at Missouri University of Science and Technology. Prior to being the vice provost, Krishnamurthy was the Associate chair for graduate affairs in the department of mechanical and aerospace engineering and engineering mechanics and associate dean for research and graduate affairs in the School of Engineering at Missouri S&T.
His research interests are related to advanced manufacturing systems, alternative energy, intelligent control and robotics. A recipient of several teaching awards at Missouri S&T, Krishnamurthy has also received the Faculty Service Excellence Award from the Missouri S&T Academy of Mechanical and Aerospace Engineers. He has served as a Boeing A. D. Welliver Faculty Summer Fellow and as an associate editor for Control and Intelligent Systems, an international journal. He is active in the Dynamic Systems and Control Division within the American Society of Mechanical Engineers. (return to contents)
M. Frederick Hawthorne is a world-renowned scientist in the field of molecular medicine and a pioneer in boron chemistry. He currently serves as the founding director of the University of Missouri International Institute of Nano and Molecular Medicine. Prior to joining the University of Missouri, Hawthorne was a university professor of chemistry at the University of California. He is a member of the U. S. National Academy of Sciences and the recipient of many national and international honors, including the 2003 King Faisal Prize in Science and the American Chemical Society's 2009 Priestley Medal. Hawthorne has authored or co-authored more than 525 research articles, 30 patents, 10 book chapters and two books. (return to contents)
Kattesh V. Katti is a Curators' Professor of Radiology and Physics, Margaret Proctor Mulligan Distinguished Professor of medical research and a senior research scientist at the University of Missouri-Columbia Research Reactor.
Katti is the director of NCI-funded University of Missouri Cancer Nanotechnology Platform and the founding director of the University of Missouri Nanoparticle Production Core Facility. He attended Karnatak University in Dharwad, India, for his bachelor's degree in chemistry, physics and mathematics and completed a master's degree in science education in chemistry from the NCERT's Regional College of Education in Mysore, India. He obtained his doctorate in 1984 from the Indian Institute of Science inBangalore, India, working in monomeric and polymeric phosphazenes. In 1985, he was awarded the internationally prestigious fellowship from the Alexander von Humboldt foundation Germany for his research work at the University of Gottingen, Germany. Kattesh joined the University of Missouri-Columbia in 1990 and has pioneered the fundamental science toward the design and applications of new hydroxymethyl phosphine chemical frameworks and ligand architectures to stabilize and engineer metals/radiometals and nanometals for biomedical, materials science and catalytic applications.
His discoveries on the development of biocompatible gold and silver nanoparticles for applications in nanomedicine and environmental protection have won him worldwide acclaims. His latest work on the development of cancer-specific hybrid nanoparticles has provided impetus for their utility as cancer therapeutic and X-ray contrast agents for CT imaging/ultrasound in early detection and therapy of prostate and breast cancers.
He was recently awarded a cancer nanotechnology grant from the National Cancer Institute to establish and direct the Cancer Nanotechnology Platform at the University of Missouri with 12 other interdisciplinary faculty. He has published more than 200 publications in peer-reviewed journals and is a principal inventor on over 70 patents and invention disclosures in the chemical, biological, optical and nanotechnological aspects of cancer diagnostic/therapeutic agents and sensors. He has delivered over 300 invited lectures at national and international meetings in over 20 countries.
In over 25 years of research work spanning the areas of chemistry, physics, materials science, biomedicine and nanotechnology, Katti has championed the development of new scientific approaches to minimize the risks of global catastrophic incidents. Katti has attained global recognition for his pioneering research on green nanotechnology as it relates to the development of biocompatible gold and silver nanoparticles.
His latest discovery which describes the role of plants and plant species for the production of nanoparticles is directly related to the creation of an important symbiosis between green nanotechnology and nature. This discovery is cited as the editor's choice in the October 2008 issue of the journal of Science. Katti is the founding editor of the International Journal of Green Nanotechnology. Katti has also been honored with numerous national and international awards.
On the entrepreneurial front, Katti is the cofounder of Nanoparticle Biochem Inc. and the Greennano Company. (return to contents)
Thomas C. Melzer is a co-founder and managing director of RiverVest Venture Partners, a venture capital firm headquartered in St. Louis focusing on medical device and biopharmaceutical investments. He is a director of Goldman Sachs Bank USA and Isto Technologies Inc., a development-stage orthobiologics company, and a former director of Centerre Healthcare Corporation, the Federal Farm Credit Banks Funding Corporation, Kereos, Inc. and Residential Capital LLC, a subsidiary of GMAC.
Melzer was previously president and chief executive officer of the Federal Reserve Bank of St. Louis from June 1, 1985 through Jan. 31, 1998. He directed the activities of the bank's head office in St. Louis, as well as its three branches in Little Rock, Louisville and Memphis. In addition, he represented the bank on the Federal Open Market Committee, the Federal Reserve System's chief monetary policymaking body. He also chaired the system's committee that oversees the investment of the Federal Reserve's pension and thrift plan assets and the committee that directs the system-level activities of the 12 reserve banks in financial services provided to banks, other depository institutions and the U.S. Treasury.
Prior to joining the Federal Reserve Bank of St. Louis, Melzer was with Morgan Stanley & Co. Incorporated, New York. During his 16-year career at the firm, which began in 1968, he was involved in a variety of management activities, including in corporate finance, real estate finance and investment, and securities sales and trading. He was named a managing director in 1977, at which time he was head of administration for the firm's securities sales and trading activities. Three years later, in 1980, he became head of the U.S. Government Securities department.
Born in Philadelphia, Melzer spent his formative years in Chicago and Pasadena, Calif. He attended Stanford University, where he received a bachelor's degree in electrical engineering in 1966 and a master's of business administration degree in 1968.
Melzer is active in the community as a director of InvestMidwest Venture Capital Forum and Parents as Teachers National Center Inc., and as a member of the advisory board of the Stanford Institute for Economic Policy Research and the National Council of the Olin School of Business at Washington University. He is a former director and chairman of Junior Achievement of Mississippi Valley Inc. and has served as a member of the advisory council of Stanford University Graduate School of Business, the President's Council of Saint Louis University, which he chaired, and the Chancellor's Council of the University of Missouri-St. Louis. He has also been active in the United Way of Greater St. Louis, chairing its Loaned Executive Recruiting Committee.
Melzer is married and has two grown children. (return to contents)
Jim has worked for over thirty-five years in the Kansas City biomedical community. Currently, he serves as the executive director of the KU Center for Technology Commercialization with responsibility of managing the intellectual property of all the University of Kansas campuses. Jim's responsibilities include the commercialization of faculty research by securing patents, trademarks and copyrights, negotiating licenses, research agreements, confidentiality agreements and material transfer agreements and facilitating collaborative research initiatives with industry partners and philanthropic organizations. He also assists the management staff of spin-off companies created from the University of Kansas technologies.
Prior to joining the University of Kansas, Jim was vice president of operations for Regional Media Laboratories. Earlier, he served as the company's director of research and development and supervisor of quality control. In addition, Jim has held management positions in hospitals and private clinical laboratories throughout the greater Kansas City area.
Jim holds a bachelor's degree in medical technology, a master's degree in microbiology from the University of Missouri-Kansas City and an MBA from the Rockhurst University Executive Fellows MBA Program.
For the Association of Medical Device Manufacturers, in Washington, D.C., Jim served as a member of the board of directors, secretary and president. He was appointed by the Commissioner of the Food and Drug Administration to the Medical Device Good Manufacturing Practices Advisory Committee for a four-year term. Jim served as chairman of the Silicon Prairie Technology Association BioScience Network Steering Committee for four years and functioned as a business counselor, instructor and consultant for the Kauffman Foundation Fast Trac program for a period of 7 years. Jim has also served on the boards of University of Kansas startup companies and various business incubators. (return to contents)
Michael Detamore is an associate professor of chemical and petroleum engineering and director of the Biomaterials and Tissue Engineering Laboratory at the University of Kansas. He came to KU in 2004 after earning his bachelor's degree in chemical engineering from the University of Colorado and his doctorate in bioengineering at Rice University. He was the recipient of an NSF CAREER Award in 2009. (return to contents)
For businesses, entrepreneurs, investors, universities, institutions and scientists, Cary Levitt provides tailored and focused representation to emerging and mature businesses in the area of intellectual property and commercial law. A former general counsel to Thermadyne Holdings Corp., a publicly traded company that manufactures and sells welding and cutting equipment globally; iCrete LLC, a startup company that developed state of the art technology in the field of building materials; and Solae LLC, a joint venture owned by DuPont and Bunge, which specializes in the development and sale of soy protein. Cary witnessed first-hand the breakthroughs in genetically modified seeds and food ingredients.
Cary actively engages in the development of IP strategies, the formation of strategic alliances and partnerships, including the licensing of patents and technology, the protection of IP, including protection of trade secrets, preparation, prosecution, and enforcement of U.S. and foreign patents relating to diverse technologies such as medical products, personal care products, polymers, polymeric membranes, engineering plastics, building materials, dietary supplements, food ingredients and other technologies. He keeps tabs on industry updates to provide clients with knowledgeable counsel, insight and strategic initiatives. (return to contents)
Michael F. Nichols became the vice president for research and economic development for the University of Missouri System in November 2007. Nichols brings more than 25 years of experience in research, product development and small business startup and operation to the position, which has a statewide focus.
Nichols joined the research faculty at the University of Missouri-Columbia in 1978, leaving nine years later to create a technology-based startup. He returned to the university in 2002 as state director of the Small Business Innovation Research and Small Business Technology Transfer Assistance centers (SBIR/STTR). Most recently he directed the Office of Technology Management and Industry Relations at Mizzou.
Nichols holds eight patents, many involving high-tech coatings he developed for health care applications. An entrepreneur, he was the founder and president of one of the first companies to be spun off of University of Missouri research. The firm he currently heads, the Atomic Paint Shop, develops unique coatings with a wide variety of applications.
Nichols received his bachelor's and master's degrees from California Polytechnic State University, and his doctorate in biomedical sciences from the University of Missouri-Columbia. An adjunct associate professor, his research has been supported by the National Institutes of Health, the National Science Foundation and the Ewing Marion Kauffman Foundation. The editor of two books, he is a member of several professional societies, a journal reviewer and a consultant. (return to contents)
Jamal Ibdah received his medical degree from the University of Jordan and a doctorate degree in biochemistry from the Medical College of Pennsylvania followed by postdoctoral training applying physical chemistry principles to study lipid-protein interactions.
After completing a three-year clinical residency in internal medicine at Wake Forest University School of Medicine, Ibdah underwent clinical fellowship training in adult gastroenterology at Washington University School of Medicine and research fellowship training in the Department of Pediatrics at Saint Louis Children's Hospital. Ibdah is board certified in both internal medicine and gastroenterology.
Ibdah is professor of internal medicine, medical pharmacology and physiology, and Raymond E. and Vaona H. Peck Chair in Cancer Research. Currently Ibdah holds the positions of senior associate dean for research at the School of Medicine, director of MU Institute for Clinical and Translational Science and director of the Division of Gastroenterology and Hepatology.
Ibdah also serves on the editorial board of World Journal of Gastroenterology and is a senior editor for the Journal of Cardio Metabolic Syndrome. Ibdah has served as ad hoc member on the hepatobiliary pathophysiology NIH study section and on several NIH special emphasis panels in clinical research; he is currently a permanent charter member of the NCRR Clinical Research Review Committee.
Ibdah has devoted his research career to translational sciences in multidisciplinary environments, and his work exemplifies the translational approach from bench to bedside and back. His studies involve generation of novel knockout mouse models as a tool to translate human disease to the bench. For instance, Ibdah has carried to the bench a clinical observation of an association between liver disease in pregnant women and pediatric fatty acid oxidation disorders. This has lead to a discovery that contributed to the understanding of the pathogenesis of a disease that has been long considered to be mysterious. This seminal observation was reported in a landmark article (New England Journal of Medicine, 1999).
In subsequent work, the clinical impact of this discovery in practice has lead to an important recommendation reported in another landmark article (JAMA, 2002). Subsequently, Ibdah's work has focused on elucidating the cellular mechanisms involved in the pathogenesis of these disorders by generating knockout mouse models. Work in his laboratory has uncovered the molecular basis for a link between fatty acid oxidation disorders and sudden unexpected infant death (Journal of Clinical Investigation, 2001).
Utilizing these novel mouse models, Ibdah's work has lead to important contributions that have crossed boundaries among disciplines. For instance, recent work in Ibdah's laboratory has documented that mice with mitochondrial dysfunction are susceptible to insulin resistance and fatty liver disease (Gastroenterology, 2005) as well as to development of liver cancer (work in progress).
All studies were conducted in collaborative, multidisciplinary environments with a team approach that involved investigators in pediatrics, obstetrics, endocrinology, biochemistry, comparative medicine, cancer biology and other disciplines. Ibdah's work has been continuously funded by NIH, including an earlier career development award (KO8). Three R01 grants and a supplement to support a minority doctorate graduate student.
Ibdah is leading the University of Missouri effort in securing Clinical and Translational Science Award (CTSA) from NIH. He served as the PI on a planning CTSA grant and is currently the PI on MU's CTSA proposal.
Ibdah has a lifelong commitment to mentoring and educating young investigators. He has served on multiple doctorate graduate student committees and two mentorship committees for medical students. He has served as the primary mentor for several doctoral students in molecular medicine and nutritional sciences and mentored several postdoctoral fellowship trainees in clinical and translational research. (return to contents)
Nasser Arshadi is the University of Missouri-St. Louis Vice Provost for Research and Professor of Financial Economics. He received his Ph.D. in financial economics at the University of Nebraska-Lincoln. He has published extensively in the top economics and finance journals on capital markets and the microeconomics of corporations with an emphasis on assessing and managing risk. He has published two books on financial intermediation (Prentice Hall) and insider trading (Kluwar Academic Publishing). He has served as an economist and policy analyst at the Board of Governors of the Federal Reserve System in Washington, DC, and as a consultant to the American Bankers Association (Washington, DC), Treasury Management Association (Washington, DC), Securities Industry Automation Corporation (NYC), Deutsche Financial Services (St. Louis), and Commerce Bancshares (St. Louis). He serves on several boards. (return to contents)
In his current role as University of Missouri System vice president for information technology, Dr. Gary Allen oversees the information technology infrastructure for the University of Missouri offices, the four campuses, UM Health Care and statewide extension programs, as well as a student enrollment of more than 66,000. He also has overall responsibility for the statewide Missouri Research and Education Network (MOREnet) and MOBIUS, a statewide common library platform. Additionally, he serves as chief information officer for the University of Missouri-Columbia campus, where he oversees campus-wide computing and telecommunication operations.
Allen is an associate professor of veterinary pathobiology at the University of Missouri-Columbia College of Veterinary Medicine. He is a diplomate (specialty of virology) of the American College of Veterinary Microbiologists and has served as a member of the ACVM Board of Governors. He holds an adjunct faculty appointment in the Department of Health Management and Informatics in MU's School of Medicine, and serves on the steering committee for the recently created MU Informatics Institute. Since 2001, he has served as executive director of the University Missouri Bioinformatics Consortium, a high-performance networking and computational infrastructure for bioinformatics research and collaboration across and beyond the four campuses of the university.
Allen received his bachelor's degreein agriculture with a biochemistry emphasis, a veterinary degree from Mississippi State University, and a doctorate in microbiology from MU. He completed postdoctoral training at Texas A&M University in immunology and biochemistry and at the MU School of Medicine in medical informatics. (return to contents)
Dean Chapman is a professor of anatomy and cell biology at the University of Saskatchewan where he holds a Tier I Canada Research Chair in X-ray Imaging and is the scientific lead for the Biomedical Imaging and Therapy Beamline Projects at the Canadian Light Source Synchrotron. Before joining the University of Saskatchewan, Chapman was a member of the physics faculty and director of the Center for Synchrotron Radiation Research and Instrumentation at the Illinois Institute of Technology in Chicago. As a researcher, he has authored over 70 articles in the area of X-ray optics and diffraction enhanced imaging and has received over $23 million in funding since 2003. In addition, he holds six patents and serves as chief scientific officer for Nesch LLC, located in the Purdue Research Park in Merrillville, Ind., is a founding member of NextRay LLC, Chapel Hill, N.C., and vice president of Quercus X-ray Technologies in Oak Park, Ill. (return to contents)
Andrea Sellers, a registered patent attorney, practices in all areas of intellectual property law, with an emphasis on the chemical and biosciences fields. She has significant experience in patent prosecution, infringement counseling and licensing regarding biochemical, chemical and mechanical inventions. She also has completed extensive reviews and infringement analyses of patents directed to the pharmaceutical, agricultural chemistry and biochemistry fields. Sellers has developed particular expertise in negotiating and drafting intellectual property agreements, including complex technology development and license agreements covering a wide range of technologies. (return to contents)
Reza Derakhshani, Ph.D., joined the University of Missouri-Kansas City School of Computing and Engineering as an assistant professor in 2004. His research focuses on computational intelligence with applications in biometrics and biomedical signal analysis. He earned his doctorate and master's degrees in Computer Engineering and Electrical Engineering respectively from West Virginia University. He earned his bachelor's degree in electrical engineering from Iran University of Science and Technology. His work has been mainly funded by the National Science Foundation, and has resulted in a number of peer-reviewed publications and a U.S. patent. (return to contents)
Delbert E. Day recently retired from the Missouri University of Science and Technology (formerly the University of Missouri-Rolla) as Curators' Professor Emeritus of Materials Science and Engineering and senior investigator (formerly director) of the Graduate Center for Materials Research.
During his career as a university teacher and researcher, he published more than 360 technical papers dealing the structure, properties, and uses of glass, edited three books and received 45 U.S. and foreign patents. His patents include glass microspheres for medical and dental applications, especially for radiation therapy, glasses for vitrifying nuclear waste, optically transparent composites and high temperature ceramics.
He is co-inventor of special purpose glass microspheres, TheraSphere, which are now in commercial use at more than 100 sites worldwide to treat patients with inoperable liver cancer. He conducted the first U.S. glass melting experiments in micro gravity on NASA's Space Shuttle. He is also a co-inventor of "Glasphalt," which recycles waste glass by using it as part of the aggregate in asphalt paving. His numerous honors and awards include election to the National Academy of Engineering, distinguished life member (and past president) of the American Ceramic Society, the Presidential Award for Research and Creativity (University of Missouri), selection as the Nation's Outstanding Young Ceramic Engineer (Pace Award) by the National Institute of Ceramic Engineers, the Hosler Alumni Scholar Medal for Scientific Achievement (Pennsylvania State University), the Chancellor's Medal and Doctor of Science, Honoris Causa, (University of Missouri-Rolla) and the Outstanding Educator Award from the American Ceramic Society. He is also a fellow of the American Ceramic Society, the Society of Glass Technology (United Kingdom) and the National Institute of Ceramic Engineers. He is the former chairman and president of MO-SCI Corp in Rolla, Mo., a company he co-founded and which manufactures special purpose glasses for the health care, electronics, transportation, aerospace, chemical and sporting goods industries. He continues his work as a researcher/teacher, entrepreneur, consultant and commercial pilot/flight instructor. (return to contents)
Paul Terranova serves as the vice chancellor for research and president of the Research Institute at the University of Kansas Medical Center. He also serves as senior associate dean of research and graduate education for the University of Kansas School of Medicine. Terranova has been at the University of Kansas Medical Center for 32 years and combines exceptional experience in the laboratory to lead KUMC's research efforts.
Terranova received his doctorate from Louisiana State University. He moved to Kansas City in 1977, to pursue his postdoctoral studies focusing on the ovarian function in the department of obstetrics and gynecology at the University of Kansas Medical Center. He was appointed assistant professor in the department of physiology in 1977, and continued on to become professor in 1985.
Terranova served as director of the Center for Reproductive Sciences from 1995-2007. He has served on the editorial boards for Endocrinology, Endocrine, Biology of Reproduction and the Journal of Pharmacology and Experimental Therapeutics. Additionally, he served on several National Institute of Health and NationalScience foundation review panels as well as for the National Academy.
Since 1979, Terranova's research has been supported by the National Institute of Health and numerous other private and national agencies. He has over 150 peer reviewed publications and book chapters. His research focuses on the regulation of ovarian function, including ovarian cancer. Terranova developed a mouse model for events related to ovarian cancer. This model has served as a basis for development of several mouse ovarian cancer epithelial cell lines for use in the syngeneic model. (return to contents)
Mohamed N. Rahaman is professor of materials science and engineering and director of the Center for Bone and Tissue Repair and Regeneration at Missouri University of Science and Technology, where he has been a faculty member since 1986. His main research interests are in the areas of biomaterials for orthopaedic applications and tissue engineering. Rahaman is the author or co-author of more than 175 publications and the author of four books. (return to contents)
Joseph A. Heppert is currently associate vice provost for research and graduate studies at the University of Kansas. Heppert chaired the KU chemistry department from 2005 -2009 and was the founding director of the university's Center for Science Education from 2001-2009. He received a bachelor's degree in chemistry with an emphasis in radiochemistry from San Jose State University in 1978, where he participated in summer research at the Lawrence Livermore National Laboratory. He was awarded a doctorate in inorganic chemistry from the University of Wisconsin-Madison in 1982, studying boron hydride chemistry with Donald Ganies, and completed postdoctoral study at Indiana University in the area of transition metal alkyl and alkoxide chemistry under the direction of Malcolm Chisholm. He was appointed assistant professor of chemistry at KU in 1985, where he currently holds the rank of professor.
Heppert's group isolated and characterized the first class of stable terminal transition metal carbide compounds. These compounds could be an important link in understanding the conversion of CO and H2 produced from coal into hydrocarbon fuels though the Fischer-Tropsch process. Terminal ruthenium carbide complexes are formed through metathesis reactions involving ruthenium alkylidenes and methylene cyclopropene compounds. The initial products of this reaction are styrene and a ruthenium cyclopropylidene complex. The cyclopropylidene intermediate extrudes dimethylfumarate leaving the ruthenium carbide functional group. Related ruthenium precursors bearing pyridine ligands do not react with methylene cyclopropenes to produce isolable ruthenium carbide complexes. Rather, these reactions generate ruthenium vinylidene compounds from the isomerization of an intermediate in the cyclopropylidene cleavage reaction. The Heppert group has investigated the mechanism of formation and reactivity of these unique compounds. These studies are relevant to understanding chemical processes catalyzed by rurthenium alkylidene complexes. Ruthenium alkylidene catalysts have become a powerful tool in the selective synthesis of a range of organic molecules, including a wide variety of new biologically active compounds.
Heppert has also been active in funded projects to improve science teaching and science teacher preparation. He sits on Sen. Pat Roberts Advisory Committee on Science, Technology and the Future, is past chair of the American Chemical Society's Committee on Education and works with the KU Center for Teaching Excellence on the introduction of more innovative teaching strategies in the natural sciences. Heppert is currently the PI of a National Mathematics and Science Institute award to replicate the UTeach model of math and science teacher preparation at KU. UKanTeach currently has over 160 enrollees at the beginning of its third year of implementation. He is directs a project to create a regional educational research consortium drawing on the expertise of social science, science and education researchers from KU, the University of Missouri-Columbia, the University of Missouri-Kansas City and Kansas State University. This consortium is engaged in collaborative research focusing on educational policy, classroom practice and student achievement with thirty two partner school districts in the Kansas City metropolitan area. The Ewing Marion Kauffman Foundation has provided major funding in support of this program. (return to contents)
Kevin Truman is dean of the School of Computing and Engineering, where he supports development and application of technology to fields such as education, nursing, medicine and dentistry.
Truman knows the impact of technology in improving health care outcomes; his faculty uses research tools, such as the GAIT lab, to conduct studies that may eliminate fall risk among the balance-impaired, uses computational modeling to model knee behavior and components to predict the effects of certain motions, loads and material properties that affect injury potential to dancers, athletes and workers.
Also, Truman has taken steps to increase the participation of people with disabilities in STEM education programs and pathways. SCE also conducts numerous programs to attract girls, women and minorities to computing and engineering. (return to contents)
Ann Smith is professor of molecular biology and biochemistry at the University of Missouri-Kansas City's School of Biological Sciences. Her research areas include the role of the heme-binding protein hemopexin in maintaining the health of the liver, spleen, placenta, eye, peripheral and central nervous systems, and the immune system. She and her research staff are supported in part by National Institutes of Health funding.
Smith and other SBS instructors provide postdoctoral research training and give undergraduate and graduate students research experience and training that prepares them for their own original post-graduate work as they develop their careers to become independent researchers. (return to contents)
Jim Thompson has been dean of the University of Missouri-Columbia College of Engineering since 1994.
He is involved in numerous professional and civic organizations including the National Society of Professional Engineers, the Missouri Society of Professional Engineers and the Rotary Club of Columbia. Professional topics of interest include our country's need for more engineers and the role of technology and higher education in economic development.
Dean Thompson received his bachelor's, master's and doctorate degree in Electrical Engineering from Texas Tech University. His areas of technical specialization include high voltage, electro-optics, electrical breakdown phenomena, pulsed power systems and devices, lasers, fast electrical and optical diagnostics, high power switches and dielectric materials.
He was elected honorary doctor of the Institute for Electrophysics in Russia in 1992 for his outstanding achievements in the areas of discharges in vacuum and high power pulsed technology. He has also been recognized for his efforts aimed at promoting scientific cooperation with the Russian Academy of Science.
Dean Thompson is a registered professional engineer; a Fellow of IEEE; a member of the American Society of Engineering Education, the Optical Society of America, IEEE Dielectrics and Electrical Insulation Society, and IEEE Nuclear and Plasma Science Society.
He is the author of numerous chapters in technical books and is the author of over 100 technical journal and presentation articles. He has served as session chairman and organizer for numerous technical meetings and panels. (return to contents)
Richard Donahue is chairman of the board and chief executive officer of Schroer Manufacturing Co. Known in the industry as Shor-Line, the company is an 83-year-old manufacturer of veterinary medical equipment.
The company is based in Kansas City, Kan. but it also has affiliated operations in Europe and Asia. Shor-Line specializes in the manufacture and sale of products with companion animal applications including kennels, tables, lights, scales and rehabilitative devices.
Donahue also serves on the executive committee of the Kansas Bioscience Organization and as a director of Pacific Greetings, a distributor and licensee for Hallmark Cards, Crayola and certain Disney properties in various Asian countries. He is a graduate of Rockhurst University and the University of Notre Dame School of Law. Donahue resides with his wife and daughters in Leawood, Kansas. (return to contents)
Cindy Kiel currently serves as the assistant vice chancellor for research services and executive director of the Office of Sponsored Research Services at Washington University in St. Louis. Prior to her arrival at Washington University, she held the position of executive director for sponsored programs at the University of Nevada, Reno, and also served as parliamentarian of the faculty senate there. She worked in research administration at the University of Utah and, prior to her academic experience, practiced law in the areas of corporate and employment law, governmental defense work and intellectual property. She is a graduate from the University of Utah College of Law. Cindy has spoken nationally and internationally on a variety of topics, including federal false claims act litigation, the ethical conduct of research, winning proposal development, financial compliance, international research collaborations, and negotiation tactics. She holds distinguished faculty recognition in the Society of Research Administrators International, and received the organization's Best Concurrent Session award in 2008. (return to contents)
Cydney Boler represents bioscience and health care companies with clinical research compliance, clinical trial and research contracting, good clinical practices, submission of investigational new drug applications, investigational device exemption applications and preparation of new drug applications. Cydney has experience negotiating, reviewing and advising on grants and contracts for federally-funded and privately-funded research projects. Cydney counsels clients on FDA regulatory compliance, preparing and reviewing agreements related to clinical trials, and licensing of FDA-regulated products. Cydney also works with companies on antitrust matters for the FTC specializing in generic drug and bioequivalance litigation. (return to contents)
Walter Leon-Salas joined the University of Missouri-Kansas City's Department of Computer Science Electrical Engineering as an assistant professor in August 2007 where he teaches analog and mixed-signal integrated circuit design courses. He received a doctorate degree in electrical engineering from the University of Nebraska-Lincoln in December 2006. His research interests include on-sensor processing, data compression, analog-to-digital conversion, integrated circuits for biomedical applications and ultra-wideband communication systems. (return to contents)
John Lauriello specializes in the diagnosis and treatment of psychotic disorders, most notably schizophrenia. In June 2009, he became only the third permanent chair of the MU department of psychiatry in its 50 year history. Prior to coming to the University of Missouri, Lauriello was the clinical vice chair at the University of New Mexico. There he directed the UNM Schizophrenia Research Group, which focused on clinical trials and neuroimaging. He was executive medical director of the UNM Psychiatric Center for nearly a decade, and he served as a UNM site principal investigator for the Mental Illness and Neuroscience Discovery Institute, a consortium of universities, schools of medicine, brain research institutions and laboratories in Minnesota, Massachusetts and New Mexico.
MIND and the National Institutes of Health have provided continuous and significant funding for Lauriello's research. In his last year in New Mexico, the NIH awarded an $11.6 million grant to the Mind Research Network to develop a center he lead for studying the neural mechanisms of schizophrenia. He served as principal investigator for that project as well as other studies involving atypical antipsychotic therapies, biomedical informatics, imaging and neurochemistry.
A graduate of Yale University in New Haven, Conn., Lauriello completed medical school at Temple University in Philadelphia and residency at New York Presbyterian Hospital's Payne Whitney Psychiatric Clinic. He completed fellowships focused on psychopharmacology and psychobiology in California at Stanford University and the University of San Diego. He had been with the University of New Mexico since 1994.
Lauriello holds the University of Missouri Chancellor's Chair of Excellence in Psychiatry. (return to contents)
Mark Hoffman is vice president for life sciences solutions at Cerner and is responsible for Cerner's life sciences development initiatives, including genomics, Health Data, clinical trials, Galt, the Cerner Discovere and HIV Insight solutions. In his current role, Hoffman is charged with reducing the barriers between patient care and clinical research.
Hoffman joined Cerner in 1997, and he has served as a software engineer, team lead, manager, solution manager and director. During his Cerner tenure, Hoffman led a team that incorporated genomic information into the electronic medical record, positioning Cerner as a leader in personalized medicine. He led the Cerner Flu Pandemic Initiative to connect more than 800 health care facilities for influenza surveillance.
Hoffman earned a bachelor's degree in molecular biology from William Jewell College in Liberty, Mo., and a doctorate in bacteriology from the University of Wisconsin-Madison. He also completed a bioethics study from Oxford University while at William Jewell. (return to contents)
Paul S. Dale is a professor of surgery and chief of the Division of Surgical Oncology at the University of Missouri-Columbia, Ellis Fischel Cancer Center. He holds a Margaret Proctor-Mulligan Professorship in Breast Cancer Research and is co-director of the MU Biodesign and Innovation Program. Since joining the university, Dale has been co-PI on several grants and has two medical instrumentation patents in progress. Dale is active in translational research with the Division of Biomedical Engineering and his clinical practice includes cancers of the breast, liver, gastrointestinal and melanoma. (return to contents)
Robert Hanson is a partner in Sonnenschein Nath & Rosenthal LLP's intellectual property group that specializes in the patenting of biotechnology and life sciences inventions. He has prosecuted more than 500 patents to issuance in the area for university, non-profit and major private industry clients. Hanson's experience includes worldwide prosecution of patent applications, invalidity/non-infringement opinions, counseling, interferences, opposition proceedings, appeals and strategic patent portfolio management and evaluation. (return to contents)
Steve Wyatt was named vice provost for economic development for MU on January 1, 2010. His responsibilities focus on MU's economic development agenda, which includes MU as an economic enterprise, targets how MU supports other Missouri enterprises, and how MU supports economic development in the state and the community. He maintains oversight of the Provost's seven functional economic development committees:
Prior to this appointment, Steve served as the associate dean for entrepreneurship and economic development and statewide business development program director for University of Missouri College of Engineering and University Extension. Steve's key responsibility was to provide entrepreneurship leadership within the College of Engineering. In addition, Steve provided leadership for the Missouri Small Business Development Centers, Missouri Procurement Technical Assistance Centers, University Center for Innovation and Entrepreneurship, Missouri Federal and State Technical program, Career Options, Missouri Market Development, Missouri Film Office, and various environmental programs.
Steve began his involvement with the University as a Missouri Small Business Development Centers (SBDC) counselor in 1987. He became the associate director for the Missouri SBDC in 1989. As associate statewide director, he provided leadership for the internal operations of the SBDC, provided legal assistance to University Extension and directed the Missouri Procurement Assistance Center. In 2001, Steve became the statewide business development program director, and in September of 2008, was named associate dean in the College of Engineering and Extension Professor.
Since 2002, Steve has served on the Director's Council for the national eXtension Initiative and Foundation.
Steve received his BS degree in business administration from the Liberty University in Virginia, in 1986, his MBA from the University of Missouri in 1989, and his JD from the University of Missouri in 1990. He is a member of the Missouri Bar and practices law on a part-time basis.
Steve is certified as an Economic Development Finance Professional by the National Development Council. He is married to Tamela and has three children. (return to contents)
Chris Fender, director of the Office of Technology Management and Industry Relations (OTMIR) at the University of Missouri-Columbia, is responsible for stimulating the development and commercialization of advanced technology and transforming University of Missouri intellectual property into successful business enterprise. OTMIR consists of ten full-time and four part-time staff dedicated to identifying, assessing, protecting, and marketing commercially viable, intellectual property developed at the University of Missouri-Columbia.
Prior to this position, Chris served as interim director and as senior licensing and business development associate for the University of Missouri. His industrial research and experience includes previous service with Monsanto Company, Asgrow Company and Servi-Tech, Inc.
Chris earned a B.S. degree in Plant Sciences and a M.S. degree in Agronomy at the University of Missouri. His research focused on the development of NIR-based, marker assisted selection for soybean breeding.
On behalf of MU, Chris interacts with faculty, community, business and state government leaders to promote University of Missouri intellectual property. As a U.S. Patent co-inventor, Chris understands the value of intellectual property and the invention to commercialization process. (return to contents)
Yinfa Ma received his BS degree in chemistry at December 1981 at Zhengzhou University in China. Ma received his Ph.D. in analytical chemistry and a minor Ph.D. in biochemistry in December 1990 from Iowa State University. From January 1991 to 2001, Ma serviced as assistant professor and associate professor in chemistry at Truman State University (Kirksville, MO). He joined the chemistry department at Missouri University of Science and Technology (formerly University of Missouri-Rolla) in 2001. During his services at Truman State University and Missouri University of Science and Technology, he has received numerous awards for his teaching and research, including Missouri Professor of the Year (1996), Governor's Award (1996, 2008) and J. Calvin Giddings Award for Excellence in Education by American Chemical Society in August 17, 2008. He is currently a Curator's Teaching Professor at Missouri S&T. Ma has published 81 peer-reviewed papers and gave 185 conference presentations. (return to contents)
Mark Johnson received his Ph.D. in Biochemistry from the University of Minnesota through the Mayo Graduate School of Medicine (Mayo Clinic, Rochester, MN) in 1980. He did post-doctoral training at Baylor College of Medicine and then held faculty positions at St. Jude Children's Research Hospital, The University of Akron and Creighton University School of Medicine before joining the Department of Oral Biology at the UMKC School of Dentistry in 2005. While at Creighton University in Omaha, he spent 12 years in the Osteoporosis Research Center. It was during this time that his group, in collaboration with Genome Therapeutics (Waltham, Mass.), identified a mutation in the low density lipoprotein receptor related protein 5 (LRP5) that causes a high bone mass (HBM) phenotype in a human kindred. LRP5 is a coreceptor for Wnt ligands and regulates the Wnt/beta-catenin signaling pathway. The discovery of the HBM mutation has been a catalyst for research efforts worldwide investigating the role of this pathway in the regulation of bone mass and as a target for pharmaceutical development to treat diseases such as osteoporosis. Johnson has authored numerous articles, reviews and book chapters on the role of Wnt signaling in the regulation of bone mass and the genetics of bone mass. His laboratory is currently focusing on the role of this pathway in the mechanism by which bone responds to mechanical loading. (return to contents)
Dr. Neil C. Olson was appointed dean of the University of Missouri College of Veterinary Medicine in 2007.
Olson earned a bachelor's degree in veterinary science in 1973 and a doctorate of veterinary medicine in 1975 from the University of Minnesota. He also earned a doctorate in physiology from Michigan State University in 1982.
Joining the faculty at North Carolina State University in 1982, Olson went on to hold a number of administrative appointments there, including director of graduate programs, director of the Summer Research Internship Program, and director of the Biomedical Imaging Center. He was appointed associate dean for research and graduate studies in 1998.
In 1979, Olson received a National Research Service Award from the National Institutes of Health. He also was awarded an Outstanding Scientist Award from Sigma Xi in 1986, received the Distinguished Scholarly Achievement Award at the NCSU Honors Convocation in 1986 and was recognized with the Basler Taler Coin Award in Recognition for Outstanding Research in Animal Health in 1993. He has served as a chairman at the annual meetings of the Research Workers in Animal Disease and the Comparative Respiratory Society. He also was elected to the National Board of Directors for the Comparative Respiratory Society in 1985 and 1991. Olson's research has focused on cardiopulmonary pathophysiology and animal models of human disease.
Since accepting the position as dean of the MU College of Veterinary Medicine, Olson has served on numerous boards and councils, including the University of Missouri Economic Development Council as chairman of the Committee to Attract New Businesses, the Board of Directors for the Missouri Innovation Center at the University of Missouri in Columbia, and the American Royal Board of Directors in Kansas City. He is also on the Kansas City Animal Health Corridor Advisory Board and is a member of the Missouri Veterinary Medical Association Executive Board in Jefferson City. (return to contents)
Ashim Mitra is currently chairman of pharmaceutical sciences and vice provost for interdisciplinary research at the University of Missouri-Kansas City. He is also the director of translational research at UMKC School of Medicine and a University of Missouri Curators' professor of pharmacy. Mitra was recently named one of two recipients for the 2007 ARVO/Pfizer Ophthalmics Translational Research Award. He received a doctorate in pharmaceutical chemistry from the University of Kansas in 1983.
Mitra joined his current position in 1994 after serving as an associate professor in the School of Pharmacy at Purdue University. He has authored and co-authored more than 250 research articles, book chapters and review papers. He is the recipient of a number of research awards from the National Institutes of Health, the American Association of Pharmaceutical Scientists, the American Association of Colleges of Pharmacy, and numerous pharmaceutical organizations. He has served as the editor of a book titled "Ophthalmic Drug Delivery Systems," which is currently in its second edition, and co-editor of "Advanced Drug Delivery Reviews." He has also made significant contributions in the area of ocular drug delivery.
Mitra's research group is developing a transporter/receptor based prodrug design for the targeted delivery of antiviral agents. His research interests are nasal and pulmonary delivery of macromolecular drugs particularly peptides and proteins. He has been elected a fellow of AAPS. (return to contents)
Brian Clevinger is a founder and managing director of Prolog. He has 20 years of experience in all phases of commercial technology development. He currently focuses on drug delivery, aesthetic materials and devices, and plant biotechnology. Previously, following an academic career in a tenured position at Washington University in St. Louis, he learned the art of investing at an affiliate of Alafi Capital and then served as founding CEO of a vaccine delivery company. Brian holds a doctorate in immunology from Indiana University and has completed his postdoctoral fellowship at Washington University. (return to contents)
Peter Sutovsky, Ph.D., is an Associate Professor of Animal Sciences, also appointed as Associate Professor of Clinical Obstetrics & Gynecology at the Departments of OBGYN and Women's Health in the School of Medicine, University of Missouri. Since the early 90's, Peter has studied mammalian gametogenesis, fertilization, and pre-implantation embryonic development, with special emphasis on the gamete and zygotic ubiquitin system. He holds five US patents, reflecting his involvement in technology development and commercialization. He was recently recognized as the inaugural recipient of the USDA-NRI Discovery Award, Big 12 Raising Star Award and CAFNR Distinguished Researcher Award. His work on fertilization and infertility has been funded by USDA, NIH, NIJ, Missouri Life Sciences Trust Fund and various other public and private entities. He has been serving as Section Editor, Associate Editor and Editorial Board Member in a number of distinguished journals in cell and reproductive biology. In high demand as a presenter, Peter has been the invited plenary speaker at numerous international symposia in North and South America, Europe and Asia. His laboratory maintains active collaborations with scientists in Argentina, Australia, Canada, Chile, Czech Republic, France, India, Japan, Peru, Slovakia, South Korea, Spain, United Kingdom and USA. (return to contents)
Prior to joining the NCI Alliance for Nanotechnology in Cancer, Krzysztof Ptak held research positions at Northwestern University and then at the National Institute of Neurological Disorders and Stroke, NIH. During Ptak's more than 10 years of research in experimental science, his focus was on the neurobiology of respiration and related specifically to the pathology of Sudden Infant Death Syndrome.
Dr. Ptak earned his Ph.D.s in Neuroscience from the Paul Cezanne University in Marseilles and the Jagiellonian University in Krakow. His dissertation was honored as the best doctoral thesis of the year by the Prime Minister of the Republic of Poland. In addition, Ptak is a recipient of awards from the American Physiological Society for Meritorious Research by a Young Investigator and The Ministry of Foreign Affairs of the Republic of France. He has authored and co-authored more than 20 peer-reviewed publications. In 2009, he received an M.B.A. in the Life Sciences at The Carey Business School at Johns Hopkins University. (return to contents)
Robert Duncan received his bachelor's degree in physics from MIT in 1982 and his doctorate in physics from the University of California-Santa Barbara in 1988. He has served as a professor of physics and astronomy at the University of New Mexico (UNM), as a visiting associate on the physics faculty at Caltech, as a joint associate professor of electrical and computer engineering at UNM, and as the associate dean for research in the College of Arts and Sciences at UNM.
As an expert in low temperature physics, Dr. Duncan has served as principal investigator on a fundamental physics research program for NASA. As the Director of the New Mexico Consortium's Institute for Advanced Studies at Los Alamos National Laboratory he has worked to fund major conferences and summer schools in quantitative biology, information science and technology, energy and environment, and astrophysics and cosmology. To date, Duncan has received more than $8 million in funding from various sources on research efforts that he leads as PI. He joined the University of Missouri as the Vice Chancellor for Research in August 2008, accepting responsibility for MU's research enterprise, including $250 million+ per year in contracts and grants, and MU's major research facilities, including the United States' largest research reactor in academia, multiple interdisciplinary research centers, and associated economic development and technology incubation efforts.
Duncan is a Fellow and life member of the American Physical Society. He was named the Gordon and Betty Moore Distinguished Scholar in the Division of Physics, Mathematics, and Astronomy at Caltech in 2004, and he chaired the Instrumentation and Measurement Topical Group for the American Physical Society in 2002, and the International Symposium on Quantum Fluids and Solids in 2003. He has consulted extensively to industry, co-invented and assisted in the formation of three companies in alternative energy, and in minimally invasive cancer surgery and diagnostics. (return to contents)
Rainer Bussmann joined Missouri Botanical Garden in 2007 as director of the William L. Brown Center (WLBC), and William L. Brown Curator of Economic Botany. Originally a vegetation ecologist, he focuses now on the interface between plant use, conservation and resource management. He held university appointments as assistant professor at University of Bayreuth (Germany), as associate professor and scientific director of the Lyon Arboretum at the University of Hawaii, and as research fellow at University of Texas, Austin, and has taught a wide variety of classes in the US, Germany, Africa and Latin America, using English, German, and Spanish as teaching languages.
His research interests focus on medicinal plants, neglected crops, wild crop relatives and traditional crop varieties, seed and germination ecology, natural resource management, international law in relation to intellectual property rights, ecology and environment, plant ecology and regeneration ecology, with current projects in Peru, Ecuador, Iran, India, Nepal and Kenya. (return to contents)
Kevin Sweeney is chair of Polsinelli Shughart's multidisciplinary life sciences practice group and a senior member of its corporate finance group. He has over 25 years experience handling mergers and acquisitions, public and private securities offerings, venture capital financing, technology transfer, and other complex financial and strategic transactions for clients in a wide variety of industries, with an emphasis in serving as a strategic advisor to the top management of life science companies. He is a strategic partner to many emerging and growth companies, assisting in the development and implementation of their business, financial and legal goals.
Mr. Sweeney uses his broad contacts in the national scientific, academic, business and financial communities to assist numerous emerging, growth, and established entities that advance human health, animal health, plant science, "green" and industrial technologies, and biosafety and homeland security sciences.
Polsinelli Shughart's life science practice group includes more than 50 attorneys from 10 legal disciplines (including IP, FDA regulatory, healthcare, alternative energy, corporate finance, and nonprofit tax) who serve our life science clients from offices in Washington, D.C., Chicago, St. Louis, Kansas City, Denver and Phoenix. (return to contents)
Wayne Carter is the vice president of clinical nutrition at the Hill's Pet Nutrition Center in Topeka, Kansas. Wayne joined Hill's in 2007 and brought several years of private practice experience and pharmaceutical development expertise. Prior to joining Hill's, Wayne was responsible for global clinical technology as an executive director at Pfizer in Groton, Conn. This department delivered multifaceted biomarker development to accelerate development decisions for human pharmaceuticals. Wayne attended Purdue University, earning his bachelor's degree in 1980, veterinary degree in 1984 and doctorate in 1994. Carter became board certified in the American College of Veterinary Internal Medicine in 1992. Wayne serves on several advisory boards and is vice chairman of KansasBio which is a non-profit organization to promote bioscience development in Kansas.
Hill's Pet Nutrition has been developing therapeutic and wellness foods since 1948 with the launch of Hill's Prescription diet k/d Canine for kidney disease. Today, Hill's is developing functional foods utilizing state of the art gene profiling, proteomics and metabolomics to define disease and select specific nutrients to change the disease profile toward a state of health. Hill's is also working with human cancer researchers to transfer nutrition knowledge gained from dogs and cats and apply this information to people. (return to contents)
Chi-Ren Shyu received his doctoral degree in electrical and computer engineering from Purdue University in 1999. After one year of post-doctoral training at Purdue, he joined the computer science department at the University of Missouri-Columbia in October 2000. Currently he is director of University of Missouri Informatics Institute and holds the Paul K. and Diane Shumaker Endowed Professorship in biomedical informatics. He is also affiliated with several institutions as an adjunct faculty of MU Sinclair School of Nursing, MU College of Education and University of Utah Biomedical Informatics Department. During his tenure at Mizzou, he received several awards including seven Departmental Teaching Awards, MU College of Engineering Faculty Research Award, MU College of Engineering Teaching Excellence Award and the National Science Foundation CAREER Award. He is the founding director of the Medical and Biological Digital Library Research Lab where ongoing researches are in the areas of biomedical informatics, image informatics, phenomics, geospatial informatics and data mining from large-scale biomedical databases. Project sponsors for his researches include the NSF, the National Institute of Health, the National Institute of Justice, the National Geospatial-Intelligence Agency, the National Cancer Institute, U.S. Department of Education and other organizations both for-profit and not-for-profit. (return to contents)
Daniel Lindgren is the president of Ocuscience, a medical device manufacturer in Kansas City. He holds a bachelor's degree in economics from Missouri University of Science and Technology and a master's degree in international business from the Boeing Institute, St. Louis University. Daniel has extensive experience in a variety of industries including information technology, aviation maintenance, medical device development, manufacturing and pharmaceutical science. He is a member of the International Society of Clinical Electrophysiology of Vision. Lindgren is a member at large on the executive committee for the Medical Reserve Corps of Greater Kansas City. He is also a veteran U.S. Army military police officer. (return to contents)
Debra Wawro is co-founder and an inventor of the guided-mode resonance sensor technology being commercialized by Resonant Sensors Inc. She is currently chief executive officer and chief scientist at RSI. Previously she has held management positions in operations as well as research and development engineering at Tellabs and Marconi Networks. She also lead a research lab analyzing and developing drug delivery methods for chemotherapeutic agents at the University of Texas Southwest Medical Center at Dallas. She holds a bachelor's and master's degree from the University of Texas at Arlington, and has several pending and issued patents. (return to contents)
Jingyue (Jimmy) Liu is currently the director of the Center for Nanoscience and professor in the Department of Physics and Astronomy and the Department of Chemistry and Biochemistry at the University of Missouri-St. Louis. He received his bachelor's degree in materials physics in 1982 from the University of Science and Technology Beijing, Beijing, China, and his doctorate degree in 1990 in condensed matter physics from Arizona State University. After a postdoctoral position for two years, Liu became a research scientist funded by the Shell Development Company in Westhollow, Texas, in the Center for Solid State Science at Arizona State University. In 1994 Liu joined Monsanto Corporate Research in St. Louis. He was appointed as a Science Fellow in 2000 for his technical achievements. In 2004, Liu was appointed as senior science fellow for his outstanding contributions to Monsanto's businesses. Among many awards that Jimmy received from Monsanto Company for developing proprietary technologies is the prestigious 2001 Edgar M. Queeny Award for Science and Technology, the highest award within Monsanto for scientific achievement. In September 2006, Jimmy joined University of Missouri-St. Louis as the director of the Center for Molecular Electronics and in 2007 he became the founding director of the Center for Nanoscience. Liu is a member of the scientific advisory board of the newly established St. Louis Institute of Nanomedicine, a consortium of academic and commercial partners devoted to enhancing regional infrastructure for the translational advancement of nanotechnology in medicine. Liu's research group now focuses on developing nanostructures for applications in energy, sensing and nanomedicine. (return to contents)
Jason R. Hall was nominated to be the executive director of the Missouri Technology Corporation in April 2009 by Gov. Jay Nixon, and unanimously confirmed by the MTC board of directors. Jason also serves as senior counsel for recovery and reinvestment on Gov. Nixon's Transform Missouri Initiative created to implement to the American Recovery and Reinvestment Act in Missouri.
Jason joined the Nixon administration from the St. Louis office of the international law firm Bryan Cave LLP where he had been an attorney for the prior five-and-a-half years focusing his practice on antitrust matters. During that time, Jason developed a wide range of experience representing high-technology and science-based clients, including substantial work representing the leading multi-industry licensing organizations that ushered in DVD technology. Missouri Lawyers Weekly honored Jason in 2007 as an "Up and Coming Lawyer," citing his dedication to his antitrust practice and his community involvement.
Jason received his law degree from Vanderbilt University Law School in Nashville. During law school, he served as the editor-in-chief of the Vanderbilt Law Review and as the executive director of the Vanderbilt Legal Aid Society. Jason received his bachelor's degree with honors in economics from Bates College in Lewiston, Maine, where he graduated magna cum laude and was selected for membership in Phi Beta Kappa. (return to contents)
Christopher Fulcher co-directs the Center for Applied Research and Environmental Systems at the University of Missouri-Columbia. Fulcher's applied research focuses on developing and implementing social innovations for strategic planning and decision support. His systems-based approach to decision making enables local, state, national and international public and nonprofit sector organizations to effectively address social issues using unique facilitation technologies. Fulcher integrates emerging computer technologies including geographic information systems, data visualization, community engagement tools and Internet accessibility to better serve vulnerable and underserved populations. These Web-based technologies help organizations and policy makers make more informed decisions about access, equity, and allocation of resources. Fulcher received his bachelor's degree in agricultural engineering at Texas A&M University in 1984 and his master's in agricultural economics at Texas A&M in 1985. He completed his doctorate in agricultural economics at the University of Missouri-Columbiai in 1996. In 2005 Fulcher completed his National Library of Medicine Post Doctoral Health Informatics Fellowship at the University of Missouri. He serves as a faculty member in the Division of Applied Social Sciences at the University of Missouri. (return to contents)
Rebecca A. Johnson's role as director of the Research Center for Human Animal Interaction (ReCHAI) at the University of Missouri-Columbia's College of Veterinary Medicine is a vehicle for research and programs demonstrating the possibilities for One Health. Her externally funded research program merges her work on wellness among older adults with the benefits of human-companion animal interaction. Johnson earned her bachelor's degree in nursing from the University of Dubuque in 1980, her master's degree from the University of Edinburgh, Scotland in 1982 (as a Rotary Foundation Scholar) and her doctorate from the University of Iowa in 1992. She joined the faculty at the MU Sinclair School of Nursing in August 1999 as a Millsap professor of gerontological nursing and public policy. She also holds a joint appointment in the College of Veterinary Medicine. (return to contents)
Joseph Mahoney is a practice leader for Mayer Brown's Intellectual Property Group and partner in the Chicago office. Mahoney is a registered patent attorney with a doctor of pharmacy degree, and he concentrates his practice on pharmaceutical patent law. He has been actively involved in Hatch-Waxman Act cases for more than 12 years on behalf of clients from the University of Missouri-Columbia, Solvay Pharmaceuticals, Galderma Laboratories, Besins Healthcare and Abbott Laboratories. (return to contents)
James R. Bloedel began his career in 1968 as an assistant professor in the physiology and neurosurgery departments at the University of Minnesota after receiving medical and doctorate degrees from that university and a bachelor's degree from St. Olaf College. In 1973 he established one of the first laboratories responsible for providing doctorate training for both graduate students and neurosurgical residents and for conducting a research program focused in both the fundamental and applied neurosciences.
In 1984 Dr. Bloedel became the chair of the neurobiology department at the Barrow Neurological Institute in Phoenix. While in that role, he also served as a research professor in physiology at the University of Arizona and an adjunct professor in kinesiology at Arizona State University. In addition to establishing one of the first departments in the country focused on integrative neuroscience, he co-directed two graduate training programs, one at each of the Arizona universities. During this period the research at the institute grew from a position of having no external funding to a well funded organization with a new 40,000-square foot research building.
Dr. Bloedel became the vice provost for research and advanced studies at Iowa State University in 2000. He served as dean of the Graduate College until 2003 and vice provost for research until 2005. During that period, externally funded research at ISU grew by almost 50 percent. The office also established several new centers and institutes as well as the university's research compliance office. While vice provost, Dr. Bloedel served on the board of directors of the National Association of State University and Land Grant Colleges, the executive board of the Council of Research and Graduate Education and was a charter member of the BioAlliance of Iowa, an organization the fosters economic development through university-industry interactions. He also served as president of the Iowa Research Council and the Ames Economic Development Commission.
Since fall 2007, Dr. Bloedel has served as professor and chair of the Department of Biomedical Sciences and continues to pursue research and teaching in the neurosciences. As a neuroscientist, he was funded by the National Institutes of Health for 34 consecutive years, during which he received 26 grants including a prestigious Javitts Award. He has published over 140 articles, reviews and books and was elected to the American Academy of Kinesiology and Physical Education in 2003. (return to contents)
Lesa Mitchell is a vice president with the Kauffman Foundation.
She has been responsible for the foundation’s frontier work in understanding the policy levers that influence the advancement of innovation from universities into the commercial market and the new relationships between disease philanthropy and for-profit companies.
Under Mitchell’s leadership, the Foundation is defining and codifying alternative commercialization pathways and identifying new models to foster innovation.
Mitchell was instrumental in the founding of the Kauffman Innovation Network/ iBridge Network, the Translational Medicine Alliance, the National Academies-based University–Industry Partnership and is a leader in the replication of innovator-based mentor programs across the U.S.
In addition, Mitchell serves on the boards of Gazelle Growth in Denmark, the University of Kansas Institute for Commercialization and is an advisor to the Institute for Pediatric Innovation.
Prior to joining Kauffman, Mitchell spent twenty years of her career in global executive roles at Aventis, Quintiles, and Marion Laboratories and ran an electronic clinical trials consulting business in support of global pharmaceutical clients. (return to contents)
An associate professor of psychology, he graduated with a Ph.D. in clinical psychology from the University of Illinois at Urbana-Champaign. After a brain imaging postdoctoral fellowship at the University of Pittsburgh, he became a faculty member at the University of Missouri-Columbia. His research examines the psychological and neural basis of cognitive and emotional control and their role in the development of schizophrenia and its symptoms (e.g., disorganized speech, negative symptoms). His research is also focused on understanding how to treat cognitive and neural deficits in schizophrenia and to prevent the development of schizophrenia. In addition, he is conducting research on whether early drug abuse causes damage to the prefrontal cortex and whether this increases risk for later neuropsychiatric disorders. (return to contents)
Cary Savage received his Ph.D. in clinical psychology from Oklahoma State University. He completed an internship in clinical psychology and postdoctoral fellowships in neuropsychology and functional neuroimaging at the Massachusetts General Hospital (MGH)/Harvard Medical School. He remained on the faculty of MGH and served as an assistant professor in the Department of Psychiatry at Harvard Medical School and the director of cognitive neuroscience in the Department of Psychiatry at MGH. Savage moved to Kansas City in 2003 and now serves as Director of Functional MRI in the Hoglund Brain Imaging Center and as a Professor of Psychiatry and Behavioral Sciences at KUMC. Savage’s research is funded by the National Institutes of Health (NIH) and private foundations. His research focuses on the roles of prefrontal cortex and limbic system in memory and motivational processes, and how these networks are disrupted in psychiatric and neurologic conditions. Savage has published over 90 original research and review articles. He serves on the Editorial Board of the Journal of Geriatric Psychiatry and Neurology. (return to contents)
Joseph S. Tash is director of the NIH-funded U54 Interdisciplinary Center for Male Contraceptive Research and Drug Development, and professor in the Department of Molecular and Integrative Physiology at the University of Kansas Medical Center. Tash received his Ph.D. (Cantab) in Reproductive Biology from the University of Cambridge, Cambridge, England, under the mentorship of Professor Thaddeus R.R. Mann, FRS, OBE, and was a post-doctoral fellow in the laboratory of Anthony R. Means at Baylor College of Medicine in Houston. His research, scientific publications and reviews have focused on male reproductive biology from the start, and include basic regulation of sperm motility and sperm function, and identification of testis- and/or sperm-specific components that can be targeted for development of reversible and non-reversible non-hormonal male contraceptive agents.
Dr. Tash’s U54 project is focusing on continued drug development and elucidating the mechanism of action of gamendazole, an orally active highly potent anti-spermatogenic contraceptive agent. The project is also discovering alternative chemical scaffold lead agents that target the same Sertoli cell molecular targets as gamendazole.
In new research, related agents are also being developed as single dose sterilants for male and female cats and dogs as well as for control of feral animal populations.
The Interdisciplinary Center for Male Contraceptive Research and Drug Development (PI, Dr. Tash), along with ongoing contract work (PI, Dr. Gunda Georg) under the auspices of the Contraceptive and Reproductive Health Branch of NICHD, represents a multi-university effort to develop reversible non-hormonal male contraceptive agents. The U54 center projects are supported by an Administrative Core (Barb Shull, Administrative Assistant), an Imaging Core, and a Drug Discovery and Synthesis Core (including medicinal chemistry and synthesis up to cGMP standards, high throughput screening (assay development, protein expression and purification, and library screening), x-ray crystallography, and rational drug design expertise). Additional details of the center projects and cores and their key personnel are found via the links on the center Web site.
Dr. Tash’s research is also funded by NASA to study the impact of space flight and altered gravity on male and female reproductive systems. His NASA research includes ground based studies, as well as flight experiments on the space shuttle (STS-81 and STS-84 in 1997, STS-131 in 2010) and on the Russian BION satellite scheduled for 2012. (return to contents)
David B. Henthorn, Ph.D., received his bachelor's and doctoral degrees in Chemical Engineering from Purdue University, studying under noted pioneer in Biomedical Engineering Professor Nicholas A. Peppas. David joined the Department of Chemical and Biological Engineering at the University of Missouri-Rolla (now Missouri University of Science and Technology) in 2004. His research group investigates biomaterials, biomedical microdevices, protein-polymer interactions, and new materials in biotechnology. (return to contents)
Jeffrey Townsend, executive vice president and chief of staff, is responsible for a wide swath of Cerner business, including supervision of Cerner Life Sciences, Health Employer, and much of Cerner’s cloud computing effort, the foundation of our consumer presence. These combined groups are referred to as CERN—an acronym for Consumer, Employer, Research and Networks.
Townsend is also the senior executive responsible for the Tiger Institute and the University of Missouri Health System, Cerner's second charter ITWorks client. He also oversees Marketing and KnowledgeWorks.
Additionally, Townsend focuses much of his time on the innovation, strategy and direction of Cerner solutions, financial planning and overseeing the company’s day-to-day operations as CEO Neal Patterson's proxy.
Townsend joined Cerner in 1985 as a programmer analyst, and within one year, he was named project leader of the foreign systems interface engineering team. After leaving Cerner for several years to lead a family-owned business, Townsend rejoined the company as project manager for strategic systems and product line executive for Cerner's management systems. He also served as the chief engineering officer, where he oversaw product development of Cerner Millennium®.
"I am proud of what we have achieved with Millennium, but I believe there are more big ideas yet to come," Townsend said. "After more than 30 years, Cerner is in a unique position to be able to help define and create an ideal future state where health care is simplified by connecting individuals, providers, researchers and employers to impact health outcomes."
Townsend earned a bachelor's degree in computer science from Iowa State University. (return to contents)
Carolyn Henry is a professor with dual appointments at the College of Veterinary Medicine and the School of Medicine at the University of Missouri-Columbia. After earning her doctorate in veterinary medicine from Auburn University in 1990, Henry began practicing small animal medicine in Alabama and Georgia, developing a passion for care of veterinary cancer patients. She returned to Auburn for an oncology residency and concurrent master's degree program.
Henry served on the Washington State University faculty from 1993 to 1997 before relocating to MU. She is past president of the Veterinary Cancer Society, current president of the American College of Veterinary Internal Medicine (ACVIM) Specialty of Oncology, and member of the ACVIM Board of Regents. She has authored more than 65 manuscripts, 15 book chapters and an oncology textbook. Her research interests include canine bladder cancer, mammary cancer, osteosarcoma and comparative oncology/cancer epidemiology.(return to contents)
Joerg Ohle is President and General Manager of Bayer HealthCare LLC's Animal Health Division, North America, which is a global leader in the manufacturing and marketing of parasite control products and prescription pharmaceuticals for dogs, cats, horses, cattle and swine.
Ohle is responsible for management and strategic direction of the North American animal health business. He also is a member of the worldwide Animal Health group's management committee. Ohle's 32-year career with Bayer includes a wealth of international business experience as his career has crossed several continents.
As Board Chairman of Kansas City's Animal Health Corridor initiative, Ohle has been instrumental in bringing together a dynamic community and industry partnership to globally position the Kansas City region as the pre-eminent center for animal health research and innovation.
Ohle is a member of the Kansas City Civic Council, the Greater Kansas City Chamber of Commerce and serves as a board member of the Kansas City Area Life Sciences Institute and the Greater Kansas City Community Foundation.
Ohle holds a business degree from Bayer's International Management School in Leverkusen, Germany. (return to contents)
Robert W. Atcher is currently the director of the National Isotope Data Center (NIDC), a new center established to assist the isotope production program. As director of the NIDC, Atcher is responsible for: providing scientific expertise to the program staff, production scheduling, oversight of the business office at Oak Ridge National Laboratory, shipping and distribution of both material coming into the program and shipments to customers, and communications on behalf of the center.
Isotopes managed include: accelerator produced (Sr-82, Ge-68, Na-22 and other research quantities) and reactor produced (Cf-252, Am-241, He-3, and others in research quantities). There are production sites in Brookhaven, Oak Ridge, Los Alamos, Idaho, and Pacific Northwest national laboratories, as well as at the University of Washington, University of California-Davis, University of Missouri-Columbia, Washington University in St. Louis, and the National Institutes of Health (NIH); pending agreements include the University of Pennsylvania and Texas A&M.
Atcher can provide his perspective on nuclear medicine related topics such as medical isotope production, single photon imaging, PET imaging, molecular imaging and therapeutic applications of radioisotopes. He also has experience in oncologic applications for molecular imaging and has served on the faculty in radiation oncology at the University of Chicago and University of Alabama at Birmingham. His interests in therapy are with high LET radiation such as protons, Auger electron emitters and alpha emitters.
In addition to serving as director of the NIDC, Atcher holds the title of University of New Mexico/Los Alamos National Laboratory professor of pharmacy at the University of New Mexico. He is the past program manager for the Department of Health and Human Services programs with Los Alamos National Laboratory in New Mexico. He is also the immediate past president of the Society of Nuclear Medicine (SNM) and currently heads the group’s task force on isotope, the major focus of which has recently been molybdenum-99 supply. He also chairs several committees in SNM.
Atcher has a bachelor's degree in chemistry from Washington University and a doctorate in chemistry from the University of Rochester. He also holds a master's in business administration from the University of New Mexico and a master's in journalism with a concentration in science writing from the University of Missouri-Columbia. (return to contents)
James A. Guikema is the associate vice president for research at Kansas State University and the associate dean of the Graduate School. Guikema received his bachelor's degree in biology from Calvin College in 1973. He then attended the University of Michigan, where he received his doctorate in the cellular and developmental biology program of the Biology Department in 1978. He worked for three years at the University of Missouri – Columbia as National Institutes of Health (NIH) postdoctoral fellow and joined the Kansas State University faculty in 1981 as an assistant professor of biology.
Guikema became the associate director of the NASA Specialized Center of Research and Training in Gravitational Biology at Kansas State University in 1991 and served as the senior associate director of the Division of Biology from 1994 to 1998. In 1998, he became the associate dean of the Graduate School and in 2001 was appointed associate vice president for research.
G. Sitta Sittampalam is a professor of pharmacology, toxicology and therapeutics at the University of Kansas Medical Center. He researches methods in quantitative biology and stem cell pharmacology and its applications in drug discovery. He has special interest in the integration of state-of-the-art cell high content imaging technologies and high throughput screening with engineered 3-D tissues to identify and validate novel drug targets in cancer.
Sittampalam’s current research involves isolation and characterization of circulating tumor cells and cancer stem cells, which are believed to contribute to relapse and metastasis. He believes that a thorough understanding of the biology and pharmacology of these cells, and their response to known anti-tumor agents, will advance the development of better agents to treat cancer. The detection of circulating tumor cells as diagnostic and prognostic biomarkers of metastasis is another area of interest. In addition, he is developing methods to isolate and culture these rare cells for use in drug discovery applications.
Sittampalam’s past experience in drug discovery and development at Eli Lilly and Company includes the development of several recombinant protein products that are currently on the market: human insulin, Lys-Pro human insulin, human growth hormone and activated protein C.
As deputy director of the Institute for Advancing Medical Innovation at the University of Kansas Cancer Center, Sittampalam plans to collaborate with scientists in organizing and implementing target identification, prioritization, HTS and lead optimization functions across multiple components at the KU Medical Center, the Lawrence campus and Stowers Institute of Medical Research. (return to contents)
Daniel P. Getman is the president of the Kansas City Area Life Sciences Institute. Before joining the institute, Getman was vice president of Pfizer global research and development and director of St. Louis Laboratories. As director, Getman built an effective site leadership team and established Pfizer's St. Louis Laboratories as a critical component of the global research organization focused on three strategically important areas: biotherapeutics, inflammation research and indications discovery.
Prior to his role with Pfizer, Getman worked with Pharmacia, Searle and Monsanto in St Louis. He served as senior director and co-chair of the Exploratory Development Committee, where he was responsible for the early human clinical portfolio spanning five research sites worldwide. He and his team mentored project teams to select drug candidates, effectively transition them into human clinical trials and complete human Phase II proof-of-concept studies. One of those teams brought forward Sutent, a medication used to treat renal and gastrointestinal cancer.
Getman previously held a variety of positions with Monsanto/Searle including senior director of medicinal chemistry and member of the Discovery Leadership Team. His research experience spans synthetic and medicinal chemistry in the areas of arthritis, cancer and infectious diseases, including AIDS. Getman led several large discovery projects including the HIV protease project that led to three separate licensing deals and two marketed products for AIDS patients. He is an inventor on more than 50 patents and author or co-author on more than 25 publications.
Getman received a doctorate in organic chemistry from the University of Minnesota in Minneapolis in 1982, and a bachelor's degree in chemistry from the State University of New York at Buffalo in 1977. Getman is an active member of a number of key life sciences organizations in the Kansas, Missouri and Kansas City region. (return to contents)
Jack C. Schultz is director of the Christopher S. Bond Life Sciences Center at the University of Missouri-Columbia, where he promotes and develops interdisciplinary research among 35 scientists whose interests range from plant breeding to electrical engineering. Schultz previously taught at Dartmouth College and the Vermont Law School, and he is a distinguished professor of entomology emeritus at Pennsylvania State University.
Schultz’s research and teaching interests are in chemical and molecular ecology, which is the study of how biochemistry mediates interactions among organisms. His work emphasizes the importance of understanding how individual components function in the context of complex systems. Although Schultz’s research has focused on how plants detect, identify and respond to insect attack, he has also worked with birds, reptiles, bacteria and viruses. Schultz’s discovery that plants emit volatiles (odors) in response to insects stimulated intense efforts to develop applications in agriculture, environmental monitoring and defense. His lab was also among the first to demonstrate interference between natural plant defenses and other pest control tactics, resulting in the redesign of some common biological control techniques.
Schultz’s work, done throughout North and South America, has been supported continuously by the US National Science Foundation for more than 30 years, with additional support from the USDA, the US Forest Service and the US Department of Defense. (return to contents)
Kenny Wilk was born and raised in Leavenworth County, Kan. and currently resides in Lansing, Kan. with his wife Darlene and their eleven-year old son William. In 1992, Kenny was elected to the Kansas House of Representatives. He represented the 42nd district for sixteen years. In the House of Representatives he served on several standing committees, including Education, Federal & State Affairs, Judiciary, Appropriations, Taxation, Local Government, Transportation, Financial Institutions, and Travel & Tourism. He is the past Chairman of the House Appropriations Committee, the Kansas 2000 Select Committee, Legislative Post Audit, the Legislative Budget Committee, the House Economic Development Committee and the House Taxation Committee.
In 2009 Kenny retired from Hallmark Cards, Inc. after a 31 year career. While at Hallmark he worked in a number of different assignments within the Operations Division.
Kenny currently serves on the board of directors for the National Institute for Strategic Technology Acquisition and Commercialization (NISTAC) in Manhattan, Kan. and the First State Bank & Trust in Tonganoxie, Kan. Kenny was recognized as the 2005 National Legislator of the Year by National BIO for his contributions toward the crafting and passage of the Kansas Economic Growth Act. He has a Bachelor of Arts degree from Ottawa University of Kansas City. Kenny did not seek reelection in 2008. (return to contents)
Raymond C. Tait, Ph.D., is vice president for research and a professor in the Department of Neurology & Psychiatry at Saint Louis University. He has served as the chief research officer at the university for almost two years. A psychologist, he has been active in research and treatment related to chronic pain for more than 25 years and has received grant funding from both federal and foundational sources. His research interests have focused primarily on assessment of chronic pain patients, especially clinical decision-making related to treatment and disability determination. Recent areas of interest include racial/ethnic disparities in treatment, long-term injury outcomes, and the assessment of pain in geriatric patients with advanced cognitive impairment. He also conducts research in the area of human research ethics. (return to contents)
Bob Marcusse joined the Kansas City Area Development Council (KCADC) in 1991 as president and chief executive officer. During his tenure, KCADC along with its state and local partners have attracted 26,000 new jobs and $2.9 billion in capital investment to the 18-county, bi-state Kansas City region.
Since Bob joined KCADC, the organization and its partners have worked with a variety of well-known companies to attract them to the region including:
• Kansas Speedway
• Distribution centers for Wal-Mart, Kohls, Lowe’s, Pacific Sunwear, Kimberly-Clark and Coleman
• Kokam America
• Prescription Solutions
• Fort Dodge Animal Health
• Newport Television
Bob has an extensive background in domestic and international corporate attraction, business growth and retention, and regional marketing. He has spearheaded major growth initiatives in the region such as the Kansas City Area Life Sciences Institute, KC Animal Health Corridor and KC SmartPort.
Bob's community involvement extends well beyond his role at KCADC. Bob serves on the Executive Committees of KC SmartPort and Missouri BIO. He is a member of the University of Kansas Edwards Campus Advisory Board, Rockhurst University School of Business Advisory Board and University of Missouri Economic Development Cabinet. He is immediate past chairman of the University of Kansas Medical Center Research Institute.
Bob has also held leadership positions with the Columbus (OH) Area Chamber of Commerce, the Economic Development Council for the Peoria area, Battle Creek (MI) Unlimited, and the Inland Port Authority of South Central Michigan and Foreign Trade Zone #43.
Bob graduated from Calvin College in Grand Rapids, Mich., with a Bachelor of Science degree. He received his Master of Science from Purdue University. (return to contents)
Gabor Forgacs received his doctorate from the Eötvös Lóránd University Budapest, Hungary and the Landau Institute for theoretical Physics, Moscow, in theoretical particle physics.
He later transformed himself into an experimental life scientist and, as the George H. Vineyard endowed chair professor at MU, built a successful research group in biological physics at the Department of Physics. He is also a faculty member in the Department of Biological Sciences, Biomedical Engineering and Veterinary Pathobiology. His main focus is on the relevance of physical mechanisms in early embryonic morphogenesis, the development of forms and shapes. His research in biomechanics has received international recognition. Recently he has translated his expertise into practice. His research group developed a novel tissue engineering technology based on bioprinting to build biological structures of definite topology and functionality, with potential applications in regenerative medicine, in particular organ replacement. The technology has been patented and the patents licensed by Organovo Inc. a startup biotechonology company in San Diego. Forgacs is Fellow of the American Physical Society and member of the Hungarian Academy of Sciences. (return to contents)
Meena Iyer’s research is aimed toward identifying and facilitating mechanisms of human neuroplasticity in health and disease. She is particularly interested in developing novel therapeutic techniques that enhance psychological, cognitive and motor performance. The main techniques employed are transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), neuroimaging with magnetoencephalography (MEG) and functional magnetic resonance imaging (fMRI). Recently, Meena was a fellow at the Brain Stimulation Unit, National Institute of Neurological Disorders and Stroke. (return to contents)
Sonny Bal is associate professor of orthopaedic surgery at the Department of Orthopaedic Surgery, University of Missouri-Columbia. He is an active clinician in hip and knee reconstruction; with research interests in ceramic biomaterials, tissue-engineering of cartilage, and less invasive surgical techniques. Along with his colleagues, he has authored several peer-reviewed publications, obtained extramural funding for research, and contributed to the educations of many graduate students in materials engineering. Bal holds an adjunct professor appointment at Missouri University of Science and Technology in Rolla. He also has an interest in law, and is a licensed attorney in Missouri. (return to contents)
Speakers are subject to change.